Related Experiment Video

Updated: Jun 5, 2025

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

10.0K

Multi-Omics Biomarkers for Predicting Efficacy of Biologic and Small-Molecule Therapies in Adults With Inflammatory

Liru Chen1, Chuhan Zhang1, Ruixuan Niu1

  • 1Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

United European Gastroenterology Journal
|December 10, 2024
PubMed

Insights

Identifying precise biomarkers is crucial for effective inflammatory bowel disease (IBD) treatments. This review explores omics biomarkers that predict patient responses to biologics and small molecule drugs for personalized IBD therapy.

Area of Science:

  • Gastroenterology and Precision Medicine
  • Biomarker Discovery
  • Inflammatory Bowel Disease (IBD) Therapeutics

Background:

  • Biological treatments and small molecule drugs for IBD exhibit variable efficacy.
  • Precise patient selection using predictive biomarkers is essential for optimizing therapeutic outcomes.
  • Recent advancements have identified numerous novel biomarkers through various omics approaches.

Purpose of the Study:

  • To systematically review baseline omics biomarkers that predict therapeutic responses in IBD.
  • To analyze the impact of integrating multiple omics datasets for biomarker discovery.
  • To evaluate biomarkers with potential effects across different therapeutic interventions.

Main Methods:

  • Systematic literature review of studies indexed in PubMed.
  • Analysis of omics data including genomics, transcriptomics (bulk and single-cell RNA sequencing), proteomics, microbiomics, and metabolomics.
  • Evaluation of integrated multi-omics models and specific predictive biomarkers.

Main Results:

  • Numerous omics biomarkers have been identified for predicting responses to biologics and small molecule drugs in IBD.
  • Multi-omics integration shows promise for enhancing biomarker predictive power.
  • Specific biomarkers may influence responses to multiple therapeutic agents.

Conclusions:

  • Omics biomarkers are vital for the precise selection of IBD treatments.
  • Integrating multi-omics data can improve the accuracy of predictive models.
  • Further research into specific biomarkers can advance precision medicine in IBD.
Keywords:
Crohn's diseaseadalimumabcertolizumabinflammatory bowel diseaseinfliximabprecision medicinetofacitinibulcerative colitisustekinumabvedolizumab

More Related Videos

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation07:05

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

8.2K
DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

47.2K

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
112
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
316
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119